OakChart

Nexentis Technologies Inc

NXTSBasic Materials·Agricultural Inputs·Israel·Nano·NASD·Nov 11 • 3:53 PM ET

2.30-0.26 (-10.16%)
2026-11-12 02:10 CET
Market cap
1.52 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-11.15 USD m
Free cash flow, TTM
-0.59 USD m
EPS diluted, TTM
-13.66
P/E
-
Compare

Price

NXTS against its 20, 50 and 200-day averages
2050200
0.0050.00100.006.2M12.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NXTSclose 2.3020-day 2.8350-day 5.22200-day 18.472.3052w high

98.1% under the 52-week high of 119.00 on 22 Jun 2026. 52-week low 2.14 on 5 Nov 2026. Last 15 sessions, 84.6% high to low

Volume 0.30× normal · the line is the 50-bar volume average

Profile

NXTS
52-week range, 0% of the way up
2.14119

Nexentis Technologies, Inc. is a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech. It delivers integrated solutions for sustainable energy, greenhouse gas emissions reduction and safety, quality solutions for the agri- tech market. Its products include SpuDefender and FreshProtect. The SpuDefender is designed to control the post-harvest potato sprout. The FreshProtect is designed to control spoilage-creating microorganisms on post-harvest citrus fruit. The firm operates through the following segments: Pathogen prevention and prolong shelf life and N2O emissions Global warming solutions. Nexentis Technologies was founded by Nimrod Ben-Yehuda on April 1, 2009 and is headquartered in Ness Ziona, Israel.

Employees9
IPONov 12, 2010
Beta1.99
ATR, 14d0.51
Rel volume0.30
Inst own2.36%

Snapshot

6 groups

Valuation

Index-
Market Cap1.37M
Enterprise Value-7.24M
Income-6.69M
Sales0.21M
Book/sh1.31
Cash/sh15.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees9
IPONov 12, 2010

Ratios

P/E-
Forward P/E-
PEG-
P/S6.50
P/B1.75
P/C0.15
P/FCF-
EV/EBITDA-
EV/Sales-34.50
Quick Ratio3.72
Current Ratio3.72
Debt/Eq0.23
LT Debt/Eq0.11
Option/ShortNo / Yes

Earnings

EPS (ttm)-87.60
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y79.28% 57.47%
Sales past 3/5Y- -
EPS Y/Y TTM77.92%
Sales Y/Y TTM18.94%
EPS Q/Q24.45%
Sales Q/Q-100.00%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own-
Insider Trans0.00%
Inst Own2.36%
Inst Trans33.01%
ROA-79.42%
ROE-93.11%
ROIC-316.15%
Gross Margin63.56%
Oper. Margin-2641.93%
Profit Margin-3208.23%
SMA20-18.78%
SMA50-55.95%
SMA200-87.55%
Trades-

Technical

Shs Outstand1.45M
Shs Float-
Short Float-
Short Ratio0.16
Short Interest0.01M
52W High119.00 -98.07%
52W Low2.14 7.48%
Volatility19.89% 15.70%
ATR (14)0.51
RSI (14)27.31
Beta1.99
Rel Volume0.30
Avg Volume81.20K
Volume24,470

Performance

Perf Week-17.12%
Perf Month-34.64%
Perf Quarter-76.41%
Perf Half Y-90.23%
Perf YTD-96.09%
Perf Year-97.99%
Perf 3Y-99.92%
Perf 5Y-100.00%
Perf 10Y-100.00%
Recom-
Target Price-
Prev Close2.56
Price2.30
Change %-10.16%

Peers

Mkt cap
TickerCompanyMkt cap
EVGNEvogene Ltd7.14M
PPBTPurple Biotech Ltd ADR2.41M
SLXNSilexion Therapeutics Corp2.04M
SPRCSciSparc Ltd0.82M
CANFCan-Fite Biopharma Ltd ADR4.71M
ENLVEnlivex Ltd1.93M
BRNXBrenX Ltd0.78M
XTLBX.T.L. Biopharmaceuticals Ltd ADR7.44M
NRSNNeuroSense Therapeutics Ltd3.38M
WAVEEco Wave Power Global AB ADR27.27M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lee Eun Young10% OwnerJan 29 '26Sale1.35127172479,524Mar 26 04:35 PM

News

latest 14 of 200
  • Nexentis Announces Reverse Stock Split (GlobeNewswire) -13.24%
  • Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz (GlobeNewswire)
  • Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage (GlobeNewswire) +7.27%
  • Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis (GlobeNewswire) -11.86%
  • Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google Cloud (InvestorsHub) -22.30%
  • Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud (GlobeNewswire)
  • Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board (GlobeNewswire)
  • Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery (GlobeNewswire)
  • Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign (GlobeNewswire) -7.19%
  • Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative (GlobeNewswire)
  • Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS) (InvestorsHub) -6.60%
  • Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation - Significant Premium to Initial Investment (GlobeNewswire)
  • Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery (GlobeNewswire) +155.91%
  • Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases (GlobeNewswire) -8.25%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-5200.566-642.868-2374.349-1798.589-2.057-2813.801-1330.985-194.165-25.016-87.6036
Period201720182019202020212022202320242025TTM
EPS, quarterly-63.683-56.595-95.268-27.893-18.076-44.8183.184-12.175-13.656
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26
Sales, annual0.3440.4270.1760.2320.4380.3940.263000.21
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0440.0170.0090.1410.06600.00200
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26
Shares, annual00.0010.0010.0012.8070.0030.0120.0490.3961.453
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0120.0170.0390.0490.0730.1230.1960.731.453
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.260.390.440.230.180.43
Cost of Goods Sold Incl. D&A0.110.080.000.080.190.190.090.170.14
Gross Profit-0.11-0.080.000.190.210.240.140.000.29
Selling, General and Administrative Excl. Other1.474.953.077.495.924.791.491.940.75
Research and Development0.370.180.001.930.750.500.390.600.30
Other Operating Expense0.000.000.000.000.000.000.000.000.02
Operating Income-1.58-5.03-3.06-7.30-5.71-4.54-1.35-1.93-0.48
Interest Expense0.370.120.090.010.010.040.210.04-
Unusual Expense9.23-1.151.430.990.110.270.03-0.01
Net Income Before Taxes-11.18-3.61-4.32-7.26-5.78-4.87-1.61-1.97-0.44
Income Taxes-0.02-0.020.000.000.000.000.000.000.00
Consolidated Net Income-11.16-3.60-4.32-7.26-5.78-4.87-1.61-1.99-0.44
Net Income From Continuing Operations-11.15-3.44-4.17-6.52-5.74-4.82-1.59-1.97-0.36
Net Income-11.15-4.05-5.19-6.52-5.74-4.82-1.59-1.97-0.36
EPS (Recurring)-5.74-29.99-156.74-1,189.58-2,776.45-1.98-1,777.06-2,374.32-633.41
EPS (Basic, Before Extraordinaries)-13.66-25.02-194.16-1,330.98-2,813.80-2.06-1,798.59-2,374.35-642.87
EPS (Diluted)-13.66-25.02-194.16-1,330.98-2,813.80-2.06-1,798.59-2,374.35-642.87
EBITDA-1.47-4.95-3.06-7.28-5.66-4.48-1.30-1.90-0.44
Non-Operating Income (Expense)0.000.380.271.040.05-0.01-0.020.000.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.201.881.062.560.940.630.510.440.07
Price To Sales Ratio--6.909.116.7021.4456.3180.7911.72
Gross Margin63.56--71.0252.1755.6961.852.2367.92
Operating Margin-2,641.93---2,771.52-1,449.43-1,036.84-580.93-1,098.44-112.98
Net Margin-3,208.23---2,475.81-1,456.74-1,100.23-685.89-1,121.25-83.66
Shares Outstanding1.450.400.050.010.002.810.000.000.00
Market Capitalization1.521.5214.952.0717.1956.2769.1761.2634.61

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue0.000.000.000.000.070.140.010.02
Cost of Goods Sold Incl. D&A0.110.100.010.000.010.050.080.01
Gross Profit-0.11-0.10-0.00-0.000.050.09-0.070.01
Selling, General and Administrative Excl. Other1.472.141.182.740.631.091.480.88
Research and Development0.370.280.050.010.020.120.120.01
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.58-2.24-1.18-2.74-0.58-1.00-1.55-0.87
Interest Expense0.370.10-1.200.810.040.040.08
Unusual Expense9.235.500.290.61-0.140.440.97-0.03
Net Income Before Taxes-11.18-7.450.37-4.55-1.26-1.41-2.31-0.80
Income Taxes-0.02-0.020.000.000.000.000.000.00
Consolidated Net Income-11.16-7.420.37-4.55-1.26-1.41-2.31-0.80
Net Income From Continuing Operations-11.15-7.420.43-4.55-1.19-1.37-2.26-0.79
Net Income-11.15-7.460.43-4.55-1.19-1.37-2.26-0.79
EPS (Recurring)-5.74-5.904.71-40.62-19.52-21.59-66.67-58.09
EPS (Basic, Before Extraordinaries)-13.66-12.183.18-44.82-18.08-27.89-95.27-56.59
EPS (Diluted)-13.66-12.183.18-44.82-18.08-27.89-95.27-56.59
EBITDA-1.47-2.13-1.18-2.74-0.58-1.00-1.55-0.86
Non-Operating Income (Expense)0.000.391.850.000.000.070.250.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.200.910.111.990.040.240.000.00
Price To Sales Ratio--16.8326.5516.6414.248.309.78
Gross Margin---150.00-78.7960.88-748.0961.92
Operating Margin---59,100.00--878.79-715.16-17,023.23-5,235.15
Net Margin--21,450.00--1,807.58-976.93-24,859.51-4,759.14
Shares Outstanding1.450.730.200.120.070.050.040.02
Market Capitalization1.5216.8725.5134.6121.2814.9511.987.13

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4.112.234.485.756.810.270.330.440.03
Short Term Receivables0.530.370.110.190.170.150.060.150.15
Inventories0.000.000.120.080.020.020.020.040.01
Other Current Assets1.370.850.760.250.230.060.020.040.06
Total Current Assets6.013.455.476.277.230.500.420.680.25
Net Property, Plant & Equipment0.040.010.120.220.230.070.130.090.16
Total Investments and Advances3.471.761.660.000.000.000.000.000.00
Intangible Assets10.720.000.000.000.000.000.000.000.26
Other Assets0.160.240.000.000.140.120.110.100.12
Total Assets20.415.467.246.497.600.690.660.860.54
Short Term Debt Incl. Current Port. of LT Debt0.750.010.040.070.050.080.060.020.40
Accounts Payable0.010.020.040.420.540.200.240.200.19
Other Current Liabilities0.680.870.690.230.340.500.330.260.49
Total Current Liabilities1.430.890.780.710.930.790.620.481.08
Long Term Debt0.240.000.010.040.090.160.300.040.06
Provision for Risks Charges0.000.000.000.000.170.160.140.130.13
Deferred Tax Liabilities0.74--------
Other Liabilities2.250.000.000.000.000.050.000.000.00
Total Liabilities4.670.890.790.751.181.151.070.651.27
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity16.014.756.485.856.48-0.44-0.380.22-0.44
Total Shareholders Equity16.014.756.485.856.48-0.44-0.380.22-0.44
Accumulated Minority Interest-0.28-0.18-0.02-0.11-0.07-0.03-0.02-0.01-0.29
Total Equity15.734.576.465.746.41-0.47-0.400.21-0.73
Total Liabilities & Stockholders Equity20.415.467.246.497.600.690.660.860.54
Book Value Per Share40.4296.43537.172,172.732.31-465.56-448.08283.89-1,100.39
Tangible Book Value Per Share13.3696.43537.172,172.732.31-465.56-448.08283.89-1,100.39
Full-Time Employees95381066--
Price to Book Ratio1.953.150.452.428.68-158.59-160.75158.5878.54
Return on Assets-26.62-65.54-94.97-81.47-63.45-235.62-258.74-42.44-137.96
Return on Equity-33.17-74.18-105.83-93.10-74.35----
Return on Invested Capital-24.90-109.35-100.54-97.51-73.37---139.33-
Quick Ratio4.193.876.868.667.740.610.651.320.22
Current Ratio4.193.877.028.777.760.630.681.400.23

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-11.62-4.16-5.35-7.26-5.78-4.87-1.61-1.99-0.44
Depreciation0.130.070.020.020.050.060.050.030.04
Other Funds (Non Cash)9.820.381.763.720.900.760.730.480.07
Funds from Operations-1.71-3.71-3.59-3.52-4.83-4.05-0.83-1.49-0.33
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.12-0.100.170.29-0.27-0.050.030.24-0.17
Cash from Operating Activities-0.59-3.81-3.42-3.23-5.10-4.10-0.80-1.24-0.51
Capital Expenditures-0.00-0.010.000.00-0.05-0.070.00-0.02-0.00
Net Assets From Acquisitions-0.01-0.590.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.020.000.000.000.000.01
Purchase or Sale of Investments-0.12-1.76-1.64-1.540.000.000.00-0.010.00
Purchase of Investments-0.12-1.76-1.64-1.540.000.000.00-0.010.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.00-0.87-0.250.000.00-0.02-0.01-0.010.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.12-3.23-1.89-1.52-0.05-0.08-0.01-0.040.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.000.00
Change in Capital Stock4.263.330.000.004.1010.500.430.841.02
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock4.263.330.000.004.1010.500.430.841.02
Proceedsfrom Stock Options0.001.500.000.004.1010.500.350.841.02
Issuance or Reduction of Debt, Net-0.221.38-0.090.00-0.010.270.350.34-0.11
Change in Long Term Debt-0.221.38-0.090.00-0.010.270.350.34-0.09
Issuance of Long Term Debt0.002.841.460.700.000.270.360.380.00
Reduction of Long Term Debt-0.22-1.47-1.54-0.70-0.01-0.01-0.01-0.04-0.09
Net Financing Active Other Cash Flow0.074.153.143.470.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities4.118.863.053.474.0910.730.741.180.91
Exchange Rate Effect0.03-0.01-0.010.01-0.00-0.00---
Net Change in Cash3.421.80-2.27-1.27-1.066.54-0.06-0.110.41
Free Cash Flow-0.59-3.82-3.42-3.23-5.15-4.17-0.80-1.27-0.51
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q32025Q22025Q12024Q4
Cash & Short Term Investments8.926.246.313.432.982.52
Short Term Receivables0.510.571.400.900.670.38
Inventories0.000.000.020.020.010.02
Other Current Assets0.971.420.930.670.670.49
Total Current Assets10.398.228.665.024.333.40
Net Property, Plant & Equipment0.100.100.060.070.070.06
Total Investments and Advances3.853.622.022.092.761.76
Intangible Assets4.234.330.000.000.000.00
Other Assets0.120.120.290.130.200.24
Total Assets18.6916.4011.037.757.375.46
Short Term Debt Incl. Current Port. of LT Debt0.210.361.110.000.000.01
Accounts Payable0.030.020.030.030.030.05
Other Current Liabilities2.551.350.911.030.950.84
Total Current Liabilities2.801.742.061.060.980.89
Long Term Debt0.210.110.020.710.780.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.690.72----
Other Liabilities13.210.970.270.431.910.00
Total Liabilities16.913.542.352.203.670.89
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1.9112.978.935.763.944.75
Total Shareholders Equity1.9112.978.935.763.944.75
Accumulated Minority Interest-0.12-0.11-0.25-0.21-0.24-0.18
Total Equity1.7812.868.685.553.704.57
Total Liabilities & Stockholders Equity18.6916.4011.037.757.375.46
Book Value Per Share1.3117.7645.5846.9354.1996.49
Tangible Book Value Per Share-1.6011.8345.5846.9354.1996.49
Full-Time Employees-----5
Price to Book Ratio1.951.302.866.005.403.15
Return on Assets---79.42-123.19-82.41-81.72
Return on Equity---93.11-159.86-115.63-92.49
Return on Invested Capital-526.70-57.034.79-70.29-25.28-28.91
Quick Ratio3.724.734.204.724.433.79
Current Ratio3.724.734.214.734.443.82

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q32025Q22025Q12024Q4
Net Income-11.62-6.590.15-4.58-1.26-1.42
Depreciation0.130.080.000.000.000.00
Other Funds (Non Cash)9.825.24-1.443.780.480.59
Funds from Operations-1.71-1.27-1.29-0.79-0.77-0.83
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.12-0.150.210.26-0.040.33
Cash from Operating Activities-0.59-1.42-1.07-0.53-0.81-0.50
Capital Expenditures-0.00-0.070.000.000.000.00
Net Assets From Acquisitions-0.01-0.21-0.00-0.030.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00-0.00
Purchase or Sale of Investments-0.12-0.17-0.030.07-1.18-1.69
Purchase of Investments-0.12-0.17-0.030.07-1.18-1.69
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.00-0.32-0.500.001.17
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.12-0.45-0.35-0.46-1.18-0.52
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.260.003.691.611.680.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.260.003.691.611.680.00
Proceedsfrom Stock Options0.000.003.550.011.500.00
Issuance or Reduction of Debt, Net-0.22-0.700.83-0.190.86-0.13
Change in Long Term Debt-0.22-0.700.83-0.190.86-0.13
Issuance of Long Term Debt0.000.001.600.001.11-0.13
Reduction of Long Term Debt-0.22-0.70-0.77-0.19-0.25-0.00
Net Financing Active Other Cash Flow0.072.900.000.000.000.58
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities4.112.204.521.422.530.45
Exchange Rate Effect0.03-0.00-0.01-0.01-0.01-0.00
Net Change in Cash3.420.323.080.420.54-0.57
Free Cash Flow-0.59-1.49-1.07-0.53-0.81-0.50

Revenue breakdown

Pharmaceutical Preparations2024: 210.00K
Israel2024: 31.00K
Peru2024: 8.00K
United States2024: 171.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.13%0.0M0.3M77.93K
2026-10-158.17%0.0M0.2M69.82K
2026-09-303.34%0.0M0.2M12.62K
2026-09-153.49%0.0M0.2M259.88K
2026-08-314.64%0.0M0.2M255.80K
2026-08-145.55%0.0M0.2M260.79K
2026-07-315.48%0.0M0.2M260.34K
2026-07-152.46%0.0M0.2M261.12K
2026-06-3012.62%0.0M0.2M254.62K
2026-06-152.16%0.0M0.1M5.46K
2026-05-296.43%0.0M0.1M5.33K
2026-05-155.84%0.0M0.1M4.77K
2026-04-305.90%0.0M0.1M4.48K
2026-04-1530.70%0.0M0.0M26.14K
2026-03-310.26%0.0M0.4M26.10K
2026-03-133.67%0.0M0.0M26.14K
2026-02-277.78%0.0M0.0M25.49K
2026-01-305.59%0.0M0.0M23.20K
2026-01-150.36%0.0M0.0M4.23K
2025-12-310.31%0.0M0.0M6.56K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-09SEC
2026-11-09PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-09SEC
2026-11-068-KCurrent report2026-11-05SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-198-KCurrent report2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-19PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-19SEC
2026-10-068-KCurrent report2026-09-29SEC
2026-10-05PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-05SEC
2026-09-038-KCurrent report2026-08-31SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-17EFFECTEffectiveness filing by commission orderSEC
2026-07-15EFFECTEffectiveness filing by commission orderSEC
2026-07-15SCHEDULE 13G/ASEC
2026-07-13S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-07-13POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-06-23424B5SEC
2026-06-228-KCurrent report2026-06-22SEC
2026-06-15424B5SEC
2026-06-128-KCurrent report2026-06-12SEC
2026-05-278-KCurrent report2026-05-27SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-01001721
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP3.11%
Yorkville Advisors Global, LP1.13%
UBS Group AG0.46%
VANGUARD FIDUCIARY TRUST CO0.07%
Tower Research Capital LLC0.05%
SBI Securities Co., Ltd.0.00%
Caitong International Asset Management Co., Ltd0.00%
BFC Planning, Inc.0.00%
BARCLAYS PLC0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.56%
Fidelity Series Total Market Index Fund0.01%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. NXTS. Cached 15 minutes.

Some panels did not load: ratings.